| scholarly article | Q13442814 |
| P2093 | author name string | Alla Danilkovitch-Miagkova | |
| Berton Zbar | |||
| P2860 | cites work | Cross-talk between the proto-oncogenes Met and Ron | Q22254408 |
| Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
| Defective posttranslational processing activates the tyrosine kinase encoded by the MET proto-oncogene (hepatocyte growth factor receptor). | Q33238614 | ||
| Cross-talk between CD44 and c-Met in B cells | Q33681252 | ||
| Enhanced transformation by a plasma membrane-associated met oncoprotein: activation of a phosphoinositide 3'-kinase-dependent autocrine loop involving hyaluronic acid and CD44. | Q33963349 | ||
| Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway | Q33969327 | ||
| The cadherin-catenin adhesion system in signaling and cancer | Q34124023 | ||
| Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase | Q34358610 | ||
| Invasive growth: from development to metastasis | Q34584035 | ||
| Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice | Q36326357 | ||
| Activating mutations for the Met tyrosine kinase receptor in human cancer | Q36595980 | ||
| Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth | Q36734562 | ||
| Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors | Q37356573 | ||
| Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor | Q37404891 | ||
| A novel germ line juxtamembrane Met mutation in human gastric cancer | Q40847293 | ||
| Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells | Q40893206 | ||
| Transgenic expression in the liver of truncated Met blocks apoptosis and permits immortalization of hepatocytes | Q41900830 | ||
| Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. | Q42279434 | ||
| Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). | Q42798119 | ||
| Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src. | Q42800257 | ||
| Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family | Q42812959 | ||
| Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 | ||
| Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor. | Q42824006 | ||
| Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies | Q42828980 | ||
| Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas | Q45345804 | ||
| Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 | ||
| Different point mutations in the met oncogene elicit distinct biological properties | Q53413979 | ||
| Evidence for non-covalent clusters of the c-met proto-oncogene product | Q54269961 | ||
| Heparan Sulfate-modified CD44 Promotes Hepatocyte Growth Factor/Scatter Factor-induced Signal Transduction through the Receptor Tyrosine Kinase c-Met | Q58324027 | ||
| Constitutive activation of c-Met in liver metastatic B16 melanoma cells depends on both substrate adhesion and cell density and is regulated by a cytosolic tyrosine phosphatase activity | Q71246262 | ||
| The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit | Q72560868 | ||
| Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression | Q73004517 | ||
| Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas | Q73586595 | ||
| Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas | Q77931840 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 863-867 | |
| P577 | publication date | 2002-04-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Dysregulation of Met receptor tyrosine kinase activity in invasive tumors | |
| P478 | volume | 109 |
| Q38083828 | A call to ARMS: targeting thePAX3-FOXO1gene in alveolar rhabdomyosarcoma |
| Q39692077 | A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor |
| Q39503071 | Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer |
| Q35551938 | Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells |
| Q24633986 | An overview of the c-MET signaling pathway |
| Q35222611 | Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit |
| Q33649756 | Analysis of progress and challenges for various patterns of c-MET-targeted molecular imaging: a systematic review |
| Q35041627 | Animal models of melanoma: an HGF/SF transgenic mouse model may facilitate experimental access to UV initiating events |
| Q38160838 | Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety |
| Q37312433 | Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation |
| Q37750050 | C-MET as a new therapeutic target for the development of novel anticancer drugs |
| Q36101108 | C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression |
| Q34440437 | CD34+/CD38− acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells |
| Q39841653 | Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors |
| Q37894860 | Caveolins in rhabdomyosarcoma |
| Q37505664 | Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51. |
| Q38222270 | Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer |
| Q37317264 | Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells |
| Q52640291 | Cigarette smoke enhances oncogene addiction to c-MET and desensitizes EGFR-expressing non-small cell lung cancer to EGFR TKIs. |
| Q84584265 | Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib |
| Q49414583 | Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review |
| Q47103399 | Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review |
| Q37446964 | Co-expression of cox-2, C-met and beta-catenin in cells forming invasive front of gallbladder cancer |
| Q34978329 | Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models |
| Q31062741 | Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607 |
| Q42049311 | Critical Role of S1PR1 and Integrin β4 in HGF/c-Met-mediated Increases in Vascular Integrity |
| Q38372437 | Crizotinib in the management of advanced-stage non-small-cell lung cancer. |
| Q24647566 | Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a |
| Q36452714 | Current status and perspective of antiangiogenic therapy for cancer: urinary cancer |
| Q37137050 | Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. |
| Q39500213 | Decorin and chondroitin‐6 sulfate inhibit B16V melanoma cell migration and invasion by cellular acidification |
| Q37263981 | Decorin is a novel antagonistic ligand of the Met receptor |
| Q39890089 | Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene |
| Q38912279 | Development of antibody-based c-Met inhibitors for targeted cancer therapy |
| Q40075732 | Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling. |
| Q41463125 | Differential expression of genes encoding proteins of the HGF/MET system in insulinomas |
| Q24608143 | Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197 |
| Q28505611 | Divergent functions of murine Pax3 and Pax7 in limb muscle development |
| Q36413232 | Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation |
| Q34782774 | Drug development of MET inhibitors: targeting oncogene addiction and expedience |
| Q38941681 | FOXC2 promotes colorectal cancer metastasis by directly targeting MET. |
| Q49619487 | First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors |
| Q36287691 | Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer |
| Q35550045 | Functional consequence of the MET-T1010I polymorphism in breast cancer |
| Q28186796 | Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) |
| Q40572436 | GW domains of the Listeria monocytogenes invasion protein InlB are required for potentiation of Met activation |
| Q39545863 | Ganglioside GD1a negatively regulates hepatocyte growth factor expression through caveolin-1 at the transcriptional level in murine osteosarcoma cells |
| Q96610153 | Genomic profiling in renal cell carcinoma |
| Q34442918 | Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation |
| Q33919993 | Hepatocyte growth factor promotes lymphatic vessel formation and function |
| Q37225326 | Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer |
| Q40961095 | Impact of MET inhibition on small-cell lung cancer cells showing aberrant activation of the hepatocyte growth factor/MET pathway. |
| Q39404792 | Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation |
| Q39310636 | Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K–Akt signaling |
| Q44737495 | Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy |
| Q38859217 | Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. |
| Q40431244 | Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor |
| Q34603045 | Integrins in invasive growth |
| Q34971882 | Interplay Between HGF/SF-Met-Ras Signaling, Tumor Metabolism and Blood Flow as a Potential Target for Breast Cancer Therapy |
| Q24295561 | Interplay between scatter factor receptors and B plexins controls invasive growth |
| Q28253680 | Invasive growth: a MET-driven genetic programme for cancer and stem cells |
| Q34584035 | Invasive growth: from development to metastasis |
| Q39007909 | Kaempferol suppresses bladder cancer tumor growth by inhibiting cell proliferation and inducing apoptosis |
| Q51320328 | Loss of MicroRNA-489-3p promotes osteosarcoma metastasis by activating PAX3-MET pathway |
| Q40135925 | Loss of PTEN selectively desensitizes upstream IGF1 and insulin signaling. |
| Q91789111 | MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis |
| Q82286267 | MET Signaling Pathway: A Rational Target for Cancer Therapy |
| Q54729777 | MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancers. |
| Q37485001 | MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors |
| Q38260120 | MET and Small-Cell Lung Cancer |
| Q58164582 | MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients |
| Q45968290 | MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review. |
| Q33273821 | MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions |
| Q38956316 | MET overexpression and gene amplification in NSCLC: a clinical perspective. |
| Q35208173 | MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines |
| Q51689102 | MET signaling in keratinocytes activates EGFR and initiates squamous carcinogenesis. |
| Q38675350 | MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. |
| Q47947817 | Management of Atypical Renal Cell Carcinomas |
| Q53580017 | Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing. |
| Q28077785 | Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing |
| Q33654173 | Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression |
| Q28235183 | Met, metastasis, motility and more |
| Q39153274 | Met-induced membrane blebbing leads to amoeboid cell motility and invasion |
| Q34412493 | MicroRNA-1 in Cardiac Diseases and Cancers |
| Q24648202 | MicroRNA-1/206 targets c-Met and inhibits rhabdomyosarcoma development |
| Q48246859 | Microtubule Depolymerization by Kinase Inhibitors: Unexpected Findings of Dual Inhibitors. |
| Q37876081 | Molecular Imaging for Guiding Oncologic Prognosis and Therapy in Esophageal Adenocarcinoma |
| Q45826769 | Molecular genetic analysis of the hepatocyte growth factor/MET signaling pathway in pediatric medulloblastoma |
| Q30372506 | Mutation-introduced dimerization of receptor tyrosine kinases: from protein structure aberrations to carcinogenesis. |
| Q40427081 | Negative feedback regulation of Met-dependent invasive growth by Notch |
| Q28828215 | Norstictic Acid Inhibits Breast Cancer Cell Proliferation, Migration, Invasion, and In Vivo Invasive Growth Through Targeting C-Met |
| Q37828536 | Novel mitogen-activated protein kinase kinase inhibitors |
| Q39675235 | Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model |
| Q46976409 | Oncogenic Met receptor induces ectopic structures in Xenopus embryos. |
| Q35754163 | P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin |
| Q41553643 | PD-L1 and c-MET expression and survival in patients with small cell lung cancer |
| Q30917936 | PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells |
| Q37883394 | Paradoxical action of growth factors: antiproliferative and proapoptotic signaling by HGF/c-MET. |
| Q80371652 | Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys |
| Q38450015 | Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx |
| Q57493808 | Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis |
| Q55145107 | Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. |
| Q47139946 | Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review |
| Q40456936 | RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. |
| Q51335207 | Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer |
| Q37973827 | Rhabdomyosarcomas: an overview on the experimental animal models. |
| Q33648325 | STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant |
| Q91931124 | Selection and characterization of FcεRI phospho-ITAM specific antibodies |
| Q37730020 | Selection criteria for c-Met-targeted therapies: emerging evidence for biomarkers |
| Q39385631 | Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor |
| Q92669216 | Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma |
| Q58164852 | Silencing the MET oncogene leads to regression of experimental tumors and metastases |
| Q34094632 | Small molecule c-Met kinase inhibitors: a review of recent patents |
| Q35040797 | Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents |
| Q64986290 | Sphingolipids inhibit endosomal recycling of nutrient transporters by inactivating ARF6. |
| Q58726253 | Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer |
| Q38922319 | Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery. |
| Q33760876 | Sunscreen effects on UV-induced immune suppression |
| Q40672745 | Suppression of HGF receptor gene expression by oxidative stress is mediated through the interplay between Sp1 and Egr-1. |
| Q52547784 | Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis |
| Q41969702 | Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer |
| Q35525917 | TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation |
| Q34309927 | Targeting MET Amplification as a New Oncogenic Driver. |
| Q55032209 | Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma. |
| Q24606259 | Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy |
| Q38297235 | Targeting the MET pathway for potential treatment of NSCLC. |
| Q28254690 | The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants |
| Q58566840 | The Role of PI3K in Met Driven Cancer: A Recap |
| Q41945861 | The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice |
| Q39760115 | The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells |
| Q37621003 | The function, proteolytic processing, and histopathology of Met in cancer |
| Q36158717 | Therapeutic targeting of receptor tyrosine kinases in lung cancer |
| Q40626260 | Tyrosine kinase signal specificity: lessons from the HGF receptor |
| Q33823715 | Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells |
| Q37962905 | c-MET as a potential therapeutic target and biomarker in cancer |
| Q38923535 | c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma |
Search more.